Switch theme
Sign up to access all valuation multiples
Lupin Ltd is a specialty and generic drug manufacturing company. The company produces, develops, and markets branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) globally. It has a presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, GastroIntestinal, and other drug therapy segments. The operations of the company are limited to the segments, namely pharmaceuticals which derives key revenue, and others. It also maintains a pipeline in high-barrier markets such as Inhalation, Biosimilars, and Complex Injectables. The vast majority of the company's sales are generated in the United States, followed by India, and other countries.
1983
20.1K+
LTM Revenue $2.6B
LTM EBITDA $613M
$10.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Lupin has a last 12-month revenue of $2.6B and a last 12-month EBITDA of $613M.
In the most recent fiscal year, Lupin achieved revenue of $2.3B and an EBITDA of $453M.
Lupin expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Lupin valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.9B | $2.3B | XXX | XXX | XXX |
| Gross Profit | $1.1B | $1.0B | XXX | XXX | XXX |
| Gross Margin | 56% | 46% | XXX | XXX | XXX |
| EBITDA | $213M | $453M | XXX | XXX | XXX |
| EBITDA Margin | 11% | 20% | XXX | XXX | XXX |
| Net Profit | -$177M | $50.0M | XXX | XXX | XXX |
| Net Margin | -9% | 2% | XXX | XXX | XXX |
| Net Debt | $320M | $345M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Lupin's stock price is INR 1969 (or $23).
Lupin has current market cap of INR 899B (or $10.4B), and EV of INR 898B (or $10.4B).
See Lupin trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10.4B | $10.4B | XXX | XXX | XXX | XXX | $0.83 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Lupin has market cap of $10.4B and EV of $10.4B.
Lupin's trades at 4.0x LTM EV/Revenue multiple, and 17.0x LTM EBITDA.
Analysts estimate Lupin's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Lupin and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $10.4B | XXX | XXX | XXX |
| EV/Revenue | 4.1x | XXX | XXX | XXX |
| EV/EBITDA | 18.3x | XXX | XXX | XXX |
| P/E | 30.8x | XXX | XXX | XXX |
| P/E/Growth | 1.8x | XXX | XXX | XXX |
| EV/FCF | 38.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpLupin's NTM/LTM revenue growth is 12%
Lupin's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Lupin's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Lupin's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Lupin and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 21% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 112% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 34% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 6% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 7% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 49% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lupin acquired XXX companies to date.
Last acquisition by Lupin was XXXXXXXX, XXXXX XXXXX XXXXXX . Lupin acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Lupin founded? | Lupin was founded in 1983. |
| Where is Lupin headquartered? | Lupin is headquartered in India. |
| How many employees does Lupin have? | As of today, Lupin has 20.1K+ employees. |
| Who is the CEO of Lupin? | Lupin's CEO is Ms. Vinita D. Gupta. |
| Is Lupin publicy listed? | Yes, Lupin is a public company listed on BOM. |
| What is the stock symbol of Lupin? | Lupin trades under 500257 ticker. |
| When did Lupin go public? | Lupin went public in 1995. |
| Who are competitors of Lupin? | Similar companies to Lupin include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Lupin? | Lupin's current market cap is $10.4B |
| What is the current revenue of Lupin? | Lupin's last 12-month revenue is $2.6B. |
| What is the current EBITDA of Lupin? | Lupin's last 12-month EBITDA is $613M. |
| What is the current EV/Revenue multiple of Lupin? | Current revenue multiple of Lupin is 4.0x. |
| What is the current EV/EBITDA multiple of Lupin? | Current EBITDA multiple of Lupin is 17.0x. |
| What is the current revenue growth of Lupin? | Lupin revenue growth between 2023 and 2024 was 21%. |
| Is Lupin profitable? | Yes, Lupin is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
